Joseph Horsman
Investor at Madrona
Seattle, Washington
Overview
Work Experience
Investor
2022 - Current
Investing in early stage companies at the intersection of life sciences and tech. Helping to build the next generation of companies pushing the boundaries of what is currently possible by combining cutting edge bench and data sciences.
Madrona is a venture firm that invests in early- to late-stage companies in the Pacific Northwest and beyond.
Business Development Consultant
2016
Provide business, scientific and strategic advice and analysis to cutting edge life science and biotech companies. Expertise includes due diligence, early stage business development, markets and competitive landscape research, pitch coaching, and life science research and development.
Strategic Business Development- Sequencing
2022 - 2022
Business Development Manager
2020 - 2022
Roche Molecular Systems, Inc., a molecular diagnostics company, develops and commercializes diagnostic and blood screening tests based on
Business Development Manager
2018 - 2020
Acquired by Roche Diagnostics Working to bring a new generation of disruptive DNA sequencing technologies to market. At Stratos I wear many hats: from spending time at the bench to driving long term strategic planning and product messaging. All my efforts are focused on doing whatever it takes to deliver a novel nanopore sequencing technology that will democratize the power of DNA.
Stratos Genomics develops Sequencing by Expansion (SBX), a single-molecule detection process that enables whole-genome sequencing.
Raised $55,929,000.00 from Fisk Ventures, Roche Venture Fund, Fisk Ventures, Roche Venture Fund and Fisk Ventures.
Product Manager
2017 - 2018
Driving development of novel applications for NanoString’s 3D Biology technology; assaying RNA, DNA and protein – Product Development – Market Research – Collaborations – Marketing
NanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.
Raised $873,850,000.00 from CRG.
Postdoctoral Researcher
2016 - 2017
Doctoral Student
2010 - 2016
My work focuses on leveraging a wide range of biochemical and molecular biological techniques to better understand the molecular mechanism of the response to hydrogen sulfide in C. elegans.
Associate
2013 - 2015
•Responsible for day to day operations of the a $20M Venture Fund, Directly involved in over $6 M invested in over 18 deals •Vet early stage companies in: Life Sciences, Medical Devices, IT and Clean Tech •Assess viability and subsequent diligence of business proposals, undertake technical and legal diligence on deal •Identify research with commercial potential. Work with professors and business professionals to facilitate company formation and find key leadership
Intern
2007 - 2007